Medizinische Hochschule Hannover

The Governors of the University of Alberta

Phytrix Ag

Michael Manns

Michael Houghton

D Lorne Tyrrell

Abdolamir Landi

Tim Lankisch

Tobias Weismueller

Rolf Gebhardt

Hildebert Wagner

Christian Strassburg

Angelika M Vollmar

Matthias Bahr

Gayane Hrachia Buniatian

Lorne D Tyrrell

The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.

Methods and compositions for treatment of autoimmune hepatitis

Methods of treatment of primary sclerosing cholangitis

Methods and compositions for diagnosis of inflammatory liver disease

The invention relates to a method for the prediction of the risk potential and/or diagnosis of cancerous diseases or inflammatory intestinal diseases, whereby a DNA sample is tested for the presence of polymorphic UGT1A7 allele. A positive result for a mutation is a positive indication of a sensitivity to cancerous diseases. A prediction of sensitivity to an inflammatory intestinal disease can similarly be made. A PCR amplification of the exon 1, using the DNA sample with subsequent sequence analysis is carried out in the method and the determined sequence compared with that of the wild type and the polymorphic allele. The presence or lack of mutations is monitored by sequencing the corresponding cDNA using automated fluorescent dye sequencing. The test arrangement for requires genetic detection reagents, namely the required primer or cDNAs, on a stationary support in a pre-prepared arrangement or sequence for reading off the results. The recombinant UGT1A7 enzymes are also used for therapeutic purposes.

Method for the prediction of the risk potential for cancerous diseases and inflammatory intestinal diseases and corresponding tests

The present invention relates to the use of Phyllanthus for preventing or treating connective tissue proliferations, for maintaining the level of reduced glutathione, for inhibiting lipopolysaccharide (LPS)-induced nitric oxide synthase (NOS) and for inhibiting expression of the cyclooxygenase (COX-2) protein.

Use of Phyllanthus for treating chronic inflammatory and fibrotic processes

Growing community of inventors

Isernhagen, Germany

Michael Manns